Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Carlini

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Frontiers in Endocrinology|July 25, 2012
A changing landscape in castration-resistant prostate cancer treatmentA Felici, M S Pino, Paolo Carlini
Journal of the National Cancer Institute|August 31, 2007
Re: Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression randomized trialGianluigi Ferretti, Alessandra Felici, Paolo Carlini, et al.
Lancet (London, England)|May 15, 2007
Exemestane or tamoxifen?Gianluigi Ferretti, Alessandra Felici, Paolo Carlini, et al.
Journal of the National Cancer Institute|September 13, 2007
Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized TrialGianluigi Ferretti, Alessandra Felici, Paolo Carlini, et al.
Journal of the National Cancer Institute|January 18, 2007
Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysisEmilio Bria, Paolo Carlini, Francesco Cognetti, et al.
The Oncologist|August 2, 2006
Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancerGianluigi Ferretti, Paola Papaldo, Alessandra Fabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
What is the biological significance of circulating blood levels of metalloproteinases?Gianluigi Ferretti, Alessandra Fabi, Paolo Carlini, et al.
Bone|May 26, 2007
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasisGianluigi Ferretti, Alessandra Fabi, Paolo Carlini, et al.
Expert Review of Anticancer Therapy|August 26, 2010
Early recurrence risk: aromatase inhibitors versus tamoxifenEmilio Bria, Paolo Carlini, Federica Cuppone, et al.
The Oncologist|May 25, 2006
Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancerGianluigi Ferretti, Alessandra Felici, Paola Papaldo, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Frontiers in Endocrinology|July 25, 2012
A changing landscape in castration-resistant prostate cancer treatmentA Felici, M S Pino, Paolo Carlini
Journal of the National Cancer Institute|August 31, 2007
Re: Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression randomized trialGianluigi Ferretti, Alessandra Felici, Paolo Carlini, et al.
Lancet (London, England)|May 15, 2007
Exemestane or tamoxifen?Gianluigi Ferretti, Alessandra Felici, Paolo Carlini, et al.
Journal of the National Cancer Institute|September 13, 2007
Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized TrialGianluigi Ferretti, Alessandra Felici, Paolo Carlini, et al.
Journal of the National Cancer Institute|January 18, 2007
Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysisEmilio Bria, Paolo Carlini, Francesco Cognetti, et al.
The Oncologist|August 2, 2006
Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancerGianluigi Ferretti, Paola Papaldo, Alessandra Fabi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
What is the biological significance of circulating blood levels of metalloproteinases?Gianluigi Ferretti, Alessandra Fabi, Paolo Carlini, et al.
Bone|May 26, 2007
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasisGianluigi Ferretti, Alessandra Fabi, Paolo Carlini, et al.
Expert Review of Anticancer Therapy|August 26, 2010
Early recurrence risk: aromatase inhibitors versus tamoxifenEmilio Bria, Paolo Carlini, Federica Cuppone, et al.
The Oncologist|May 25, 2006
Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancerGianluigi Ferretti, Alessandra Felici, Paola Papaldo, et al.
Pageof 8